TMEM229A

Across TCGA pan-cancer cohorts, TMEM229A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM229A data layer compared with 18 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TMEM229A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM229A expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

ESCA and SCLC are the cancer types where TMEM229A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.195	0.707	<.001	36	view →
SCLC	DFS	Median	II,III,IV	1.000	0.552	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMEM229A–ESCA (OS)

Open the ESCA breakdown →